Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated ...
Kantata today announced that it was recognized as a Leader in the IDC MarketScape: Worldwide AI-Enabled Professional Services Automation Applications (PSA) 2025-2026 Vendor Assessment (Doc US50655623 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback